Vinicio A De Jesus Perez

List of Publications by Year
in descending order

115 papers	4,528 citations	109137 35 h-index	110170 64 g-index
252 all docs	252 docs citations	252 times ranked	5470 citing authors

#	Article	IF	Citations
1	CHK yourself, before you wreck yourself: targeting the DNA damage response in secondary pulmonary hypertension. Thorax, 2022, 77, 218-219.	2.7	0
2	Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. Chest, 2022, 161, 1060-1072.	0.4	16
3	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nature Reviews Cardiology, 2022, 19, 314-331.	6.1	46
4	Health disparity is a global issue: Understanding Latin America. Pulmonary Circulation, 2022, 12, e12049.	0.8	2
5	An evidence appraisal of heart organoids in a dish and commensurability to human heart development in vivo. BMC Cardiovascular Disorders, 2022, 22, 122.	0.7	2
6	Guest Editors' Memo: Disparities in Pulmonary Arterial Hypertension Care: Challenges and Solutions. Advances in Pulmonary Hypertension, 2022, 21, 29-29.	0.1	0
7	Hispanic Ethnicity and Social Determinants of Health: Harnessing Data from The Pulmonary Hypertension Association Registry. Advances in Pulmonary Hypertension, 2022, 21, 44-48.	0.1	2
8	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 613-622.	1.5	27
9	In Defense of the Nucleus: NUDT1 and Oxidative DNA Damage in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 541-542.	2.5	3
10	Puerto Rico Health System Resilience After Hurricane Maria: Implications for Disaster Preparedness in the COVID-19 Era. Frontiers in Communication, 2021, 5, .	0.6	5
11	Hypoxia-induced inflammation: Profiling the first 24-hour posthypoxic plasma and central nervous system changes. PLoS ONE, 2021, 16, e0246681.	1.1	6
12	No Good Deed Goes Unpunished. Chest, 2021, 159, 910-911.	0.4	0
13	Pulmonary Arterial Hypertension Secondary to Drugs and Toxins. Clinics in Chest Medicine, 2021, 42, 19-38.	0.8	6
14	Distinct types of plexiform lesions identified by synchrotron-based phase-contrast micro-CT. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L17-L28.	1.3	19
15	Novel TNIP2 and TRAF2 Variants Are Implicated in the Pathogenesis of Pulmonary Arterial Hypertension. Frontiers in Medicine, 2021, 8, 625763.	1.2	13
16	Lung Pericytes in Pulmonary Vascular Physiology and Pathophysiology. , 2021, 11, 2227-2247.		19
17	Immunoprofiling of Nonarteritic Anterior Ischemic Optic Neuropathy. Translational Vision Science and Technology, 2021, 10, 17.	1.1	3
18	Prioritizing Equity and Diversity in Academic Medicine Faculty Recruitment and Retention. JAMA Health Forum, 2021, 2, e212426.	1.0	22

#	Article	IF	Citations
19	Health Disparities in Pulmonary Arterial Hypertension and the Impact of the COVID-19 Pandemic. Advances in Pulmonary Hypertension, 2021, 20, 6-15.	0.1	5
20	Targeted proteomics of right heart adaptation to pulmonary arterial hypertension. European Respiratory Journal, 2021, 57, 2002428.	3.1	16
21	Editorial: Pulmonary Hypertension in the Modern Era: Science and Clinical Practice. Frontiers in Medicine, 2021, 8, 785181.	1.2	0
22	Prescription Patterns for Pulmonary Vasodilators in the Treatment of Pulmonary Hypertension Associated With Chronic Lung Diseases: Insights From a Clinician Survey. Frontiers in Medicine, 2021, 8, 764815.	1.2	1
23	Myocardial bridge: an unrecognized cause of chest pain in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-4.	0.8	0
24	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 148-157.	2.5	53
25	Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium. Pulmonary Therapy, 2020, 6, 9-22.	1.1	38
26	Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction. Cardiovascular Diagnosis and Therapy, 2020, 10, 1580-1603.	0.7	35
27	Portopulmonary Hypertension: From Bench to Bedside. Frontiers in Medicine, 2020, 7, 569413.	1.2	31
28	Hiding in Plain Sight: The Basement Membrane in Pulmonary Vascular Remodeling. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 13-14.	1.4	2
29	Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 130-132.	2.5	56
30	Perspectives on Cardiopulmonary Critical Care for Patients With COVIDâ€19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Journal of the American Heart Association, 2020, 9, e017111.	1.6	5
31	The cancer hypothesis of pulmonary arterial hypertension: the next ten years. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1138-L1139.	1.3	5
32	Anatomic, genetic and functional properties of the retinal circulation in pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-4.	0.8	5
33	Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFRÎ². American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1445-1457.	2.5	45
34	Systemic hypoxia led to little retinal neuronal loss and dramatic optic nerve glial response. Experimental Eye Research, 2020, 193, 107957.	1.2	17
35	Mural Cell SDF1 Signaling Is Associated with the Pathogenesis of Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 747-759.	1.4	29
36	Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1407-1415.	2.5	18

#	Article	IF	Citations
37	Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature. Global Cardiology Science & Practice, 2020, 2019, .	0.3	2
38	Gender and Race Disparities in Pulmonary Hypertension Diagnosis and Treatment. Respiratory Medicine, 2020, , 195-202.	0.1	0
39	Pulmonary Vein Stenosis and Pulmonary Hypertension Following a Catheter-Based Radiofrequency Ablation for Atrial Fibrillation: A Case Report. American Journal of Case Reports, 2020, 21, e924709.	0.3	4
40	Abstract 15092: The Yin-yang of Bmpr2 and Ces1 in the Pulmonary Endothelium Aad Its Role in Pulmonary Arterial Hypertension. Circulation, 2020, 142, .	1.6	0
41	Abstract 15053: Vascular Inflammation in Pulmonary Hypertension is Exacerbated by Litaf-dependent Pericyte Signaling. Circulation, 2020, 142, .	1.6	0
42	EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1188-1190.	2.5	1
43	Clinical outcomes of inferior vena cava filter in complicated pulmonary embolism. Pulmonary Circulation, 2019, 9, 1-10.	0.8	3
44	A Unique Collateral Artery Development Program Promotes Neonatal Heart Regeneration. Cell, 2019, 176, 1128-1142.e18.	13.5	162
45	Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice. Biomaterials, 2019, 203, 52-62.	5.7	69
46	Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011. ERJ Open Research, 2019, 5, 00017-2019.	1.1	7
47	New and Emerging Therapies for Pulmonary Arterial Hypertension. Annual Review of Medicine, 2019, 70, 45-59.	5.0	68
48	Low-grade albuminuria in pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 204589401882456.	0.8	11
49	EMAPII: A Key Player in HIV-Nefâ€“induced Pulmonary Vasculopathy. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 257-258.	1.4	2
50	Loss of Endothelium-Derived Wnt5a Is Associated With Reduced Pericyte Recruitment and Small Vessel Loss in Pulmonary Arterial Hypertension. Circulation, 2019, 139, 1710-1724.	1.6	90
51	The 6th World Symposium on Pulmonary Hypertension: whatâ€™s old is new. F1000Research, 2019, 8, 888.	0.8	93
52	Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	0.8	115
53	Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 788-800.	2.5	81
54	Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L443-L460.	1.3	51

#	Article	IF	Citations
55	Methamphetamine and the risk of pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2018, 24, 416-424.	1.2	28
56	Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L967-L983.	1.3	32
57	Pulmonary Vascular Complications of Liver Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, P5-P6.	2.5	1
58	Career Development of Young Physicianâ€“Scientists in the Cardiovascular Sciences. Circulation Research, 2018, 122, 1330-1333.	2.0	6
59	Stimulants and Pulmonary Arterial Hypertension: An Update. Advances in Pulmonary Hypertension, 2018, 17, 49-54.	0.1	4
60	Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L252-L266.	1.3	35
61	Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-Î² in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1559-1569.	1.1	41
62	Long-Term Right Ventricular Adaptation to Postnatal Hyperoxia: Too Much of a Good Thing?. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 559-560.	1.4	2
63	Interleukinâ€10â€“mediated regenerative postnatal tissue repair is dependent on regulation of hyaluronan metabolismviafibroblastâ€specific STAT3 signaling. FASEB Journal, 2017, 31, 868-881.	0.2	59
64	Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, e32-e47.	2.5	36
65	Modified High-Molecular-Weight Hyaluronan Promotes Allergen-Specific Immune Tolerance. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 109-120.	1.4	30
66	MicroRNA and Cardiovascular Disease 2016. BioMed Research International, 2017, 2017, 1-2.	0.9	2
67	Inducible pluripotent stem cells and pulmonary arterial hypertension: the future is now!. Stem Cell Investigation, 2017, 4, 53-53.	1.3	0
68	Drug-Induced Pulmonary Hypertension: The First 50 Years. Advances in Pulmonary Hypertension, 2017, 15, 133-137.	0.1	3
69	Recent advances in the management of pulmonary arterial hypertension. F1000Research, 2016, 5, 2755.	0.8	15
70	<scp>PDGF</scp>â€dependent Î²â€catenin activation is associated with abnormal pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension. FEBS Letters, 2016, 590, 101-109.	1.3	46
71	Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension. American Journal of Pathology, 2016, 186, 2500-2514.	1.9	35
72	Novel Signaling Pathways in Pulmonary Arterial Hypertension (2015 Grover Conference Series). Pulmonary Circulation, 2016, 6, 285-294.	0.8	31

#	Article	IF	Citations
73	In Vivo Study of Human Endothelial-Pericyte Interaction Using the Matrix Gel Plug Assay in Mouse. Journal of Visualized Experiments, 2016, , .	0.2	6
74	Novel approaches to pulmonary arterial hypertension drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 407-414.	2.5	6
75	Loss of PPARÎ³ in endothelial cells leads to impaired angiogenesis. Journal of Cell Science, 2016, 129, 693-705.	1.2	32
76	Molecular pathogenesis and current pathology of pulmonary hypertension. Heart Failure Reviews, 2016, 21, 239-257.	1.7	45
77	Special Considerations for the Pulmonary Hypertension Patient. , 2016, , 345-358.		0
78	MicroRNA and Cardiovascular Disease. BioMed Research International, 2015, 2015, 1-2.	0.9	6
79	Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging, 2015, 8, 627-638.	2.3	44
80	Perlecan heparan sulfate deficiency impairs pulmonary vascular development and attenuates hypoxic pulmonary hypertension. Cardiovascular Research, 2015, 107, 20-31.	1.8	30
81	First among Equals: Nerve Growth Factor in the Pathogenesis of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 274-275.	2.5	0
82	Cyclosporine Does Not Prevent Microvascular Loss in Transplantation but Can Synergize With a Neutrophil Elastase Inhibitor, Elafin, to Maintain Graft Perfusion During Acute Rejection. American Journal of Transplantation, 2015, 15, 1768-1781.	2.6	14
83	Suppression of endothelial CD39/ENTPD1 is associated with pulmonary vascular remodeling in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L1046-L1057.	1.3	43
84	Activation of the Wnt/Planar Cell Polarity Pathway Is Required for Pericyte Recruitment during Pulmonary Angiogenesis. American Journal of Pathology, 2015, 185, 69-84.	1.9	60
85	Optical Coherence Tomography of Pulmonary Arterial Walls in Humans and Pigs (Sus scrofa) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	0.4	2
86	Oxido-reductive regulation of vascular remodeling by receptor tyrosine kinase ROS1. Journal of Clinical Investigation, 2014, 124, 5159-5174.	3.9	38
87	Whole-Exome Sequencing Reveals TopBP1 as a Novel Gene in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1260-1272.	2.5	70
88	Loss of Bone Morphogenetic Protein Receptor 2 Is Associated with Abnormal DNA Repair in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 1118-1128.	1.4	70
89	Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. Journal of Experimental Medicine, 2014, 211, 263-280.	4.2	123
90	Perioperative Pharmacological Management of Pulmonary Hypertensive Crisis during Congenital Heart Surgery. Pulmonary Circulation, 2014, 4, 10-24.	0.8	29

#	Article	IF	Citations
91	Current Clinical Management of Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 131-147.	2.0	55
92	Targeting the Wnt signaling pathways in pulmonary arterial hypertension. Drug Discovery Today, 2014, 19, 1270-1276.	3.2	41
93	Pumping It Up! Angiogenesis and Muscle Deconditioning in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 250-251.	2.5	5
94	Tie2-dependent VHL knockdown promotes airway microvascular regeneration and attenuates invasive growth of Aspergillus fumigatus. Journal of Molecular Medicine, 2013, 91, 1081-1093.	1.7	22
95	MiR-133a Modulates Osteogenic Differentiation of Vascular Smooth Muscle Cells. Endocrinology, 2013, 154, 3344-3352.	1.4	119
96	MicroRNAs: promising therapeutic targets for the treatment of pulmonary arterial hypertension. Expert Opinion on Therapeutic Targets, 2013, 17, 557-564.	1.5	18
97	Understanding the Pharmacokinetics of Oral Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2013, 61, 471-473.	0.8	3
98	A Case of Recurrent Pericardial Constriction Presenting with Severe Pulmonary Hypertension. Pulmonary Circulation, 2013, 3, 436-439.	0.8	4
99	FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation, 2013, 123, 3600-3613.	3.9	354
100	Effectiveness of YouTube as a Source of Medical Information on Heart Transplantation. Interactive Journal of Medical Research, 2013, 2, e28.	0.6	38
101	Loss of Adenomatous Poliposis Coli-Î±3 Integrin Interaction Promotes Endothelial Apoptosis in Mice and Humans. Circulation Research, 2012, 111, 1551-1564.	2.0	34
102	Diagnosis and Management of Pulmonary Hypertension Associated with Left Ventricular Diastolic Dysfunction. Pulmonary Circulation, 2012, 2, 163-169.	0.8	23
103	The Intersection of Genes and Environment. Chest, 2012, 141, 1598-1600.	0.4	15
104	Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, 1546-1550.	0.7	34
105	Development of a recurrent pleural effusion in a patient with pulmonary arterial hypertension treated with imatinib. Case Reports in Clinical Medicine, 2012, 01, 38-41.	0.1	0
106	Disruption of PPARÎ³/Î²-cateninâ€“mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. Journal of Clinical Investigation, 2011, 121, 3735-3746.	3.9	217
107	BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. Journal of Cell Biology, 2011, 192, 171-188.	2.3	64
108	Disruption of the Apelin-APJ System Worsens Hypoxia-Induced Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 814-820.	1.1	148

#	Article	IF	Citations
109	Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wntâ€“Î²-catenin and Wntâ€“RhoAâ€“Rac1 pathways. Journal of Cell Biology, 2009, 184, 83-99.	2.3	194
110	S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phosphoâ€“Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4. Circulation Research, 2009, 105, 639-647.	2.0	80
111	Angina Associated With Left Main Coronary Artery Compression in Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2009, 28, 527-530.	0.3	32
112	Coexistence of primary adenocarcinoma of the lung and Tsukamurella infection: a case report and review of the literature. Journal of Medical Case Reports, 2008, 2, 207.	0.4	17
113	An antiproliferative BMP-2/PPARÎ³/apoE axis in human and murine SMCs and its role in pulmonary hypertension. Journal of Clinical Investigation, 2008, 118, 1846-1857.	3.9	314
114	Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferatorâ€“Activated Receptor-Î³ Activation. Circulation, 2007, 115, 1275-1284.	1.6	344
115	Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy. Circulation Genomic and Precision Medicine, 0, , .	1.6	0